A Randomized Controlled Study to Evaluate the Effect of Nanocurcumin Supplementation on Treatment Response and Radiation-Induced Toxicities in Patients with Locally Advanced Head and Neck Cancer Undergoing Concurrent Chemoradiotherapy

Does Nanocurcumin Supplementation enhance therapeutic index of Radiation therapy in patients with locally advanced head and neck cancer undergoing concurrent chemoradiotherapy - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/113022

Enrollment

136

Registered

2026-06-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C069- Malignant neoplasm of mouth, unspecified

Interventions

Intervention1: Nanocurcumin tablets: Each tablet contains- 1.Nano-curcuminoid 500mg 2.Astaxanthin 8mg 3.Piperine 10mg 4.EPA 90mg 5.DHA 60mg 6.Excipients q.s Each tablet contains 500mg of Nanocurcumi

Eligibility

Inclusion criteria

Inclusion criteria: Histologically proven SCC of Oral cavity, oropharynx,hypopharynx or larynx Candidates for adjuvant or definitive external beam RT with cisplatin Adequate hematological parameters

Exclusion criteria

Exclusion criteria: Prior head and neck RT Curcumin hypersensitivity Active peptic ulcer disease or uncontrolled biliary disease Pregnancy or lactation Patients who refuse to give consent

Design outcomes

Secondary

Measure	Time frame
To assess & describe the incidence & severity of acute toxicity during RT & upto 4 weeks post RTTimepoint: Baseline, During radiation therapy & upto 4 weeks post completion of treatment	—

Primary

Measure	Time frame
To see the overall response rate by using Nanocurcumin as a radiosensitiser in head and neck cancer patients undergoing concurrent chemoradiotherapyTimepoint: To see the overall response rate by using Nanocurcumin as a radiosensitiser in head and neck cancer patients undergoing concurrent chemoradiotherapy at baseline and 4 weeks post RT by using Imaging modality such as CT scan or MRI	—

Countries

India

Contacts

Public ContactDr R Maya i ka Marbaniang

Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University

mohsinkhan793@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026